Shares of Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) were upgraded by analysts at Morgan Stanley to an Overweight from an Equal-Weight rating
The London-based pharmaceutical company said last week that it is generating good revenue growth and expects its revenue for the full year to grow by approximately 35% to around $2 billion in constant currency.
Hikma Pharmaceuticals manufactures branded and non-branded generic and in-licensed pharmaceutical products.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer